The DOI matches its Crossref record.
Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by COVID-19: anti-inflammatory strategies.
Abstract
COVID-19 (coronavirus disease-19) involves humans as well as animals and may cause serious damage to the respiratory tract including the lung. This pathogenic virus has been identified in swabs performed on the throat and nose of patients who suffer from or are suspected of the disease. When COVID-19 infect the upper and lower respiratory tract it can cause mild or highly acute respiratory syndrome with consequent release of pro-inflammatory cytokines, including interleukin (IL)-1b and IL-6. The binding of COVID-19 to the Toll Like Receptor (TLR) causes the release of pro-IL-1b which is cleaved by caspase-1, followed by inflammasome activation and production of active mature IL-1b which is a mediator of lung inflammation, fever and fibrosis. Suppression of pro-inflammatory IL-1 family members and IL-6 have been shown to have a therapeutic effect in many inflammatory diseases, including viral infections. Cytokine IL-37 has the ability to suppress innate and acquired immune response and also has the capacity to inhibit inflammation by acting on IL-18Ra receptor. IL-37 performs its immunosuppressive activity by acting on mTOR and increasing the adenosine monophosphate (AMP) kinase. This cytokine inhibits class II histocompatibility complex (MHC) molecules and inflammation in inflammatory diseases by suppressing MyD88 and subsequently IL-1β, IL-6, TNF and CCL2. The suppression of IL-1b by IL-37 in inflammatory state induced by COVID-19 can have a new therapeutic effect previously unknown. Another inhibitory cytokine is IL-38, the newest cytokine of the IL-1 family members, produced by several immune cells including B cells and macrophages. IL-38 is also a suppressor cytokine which inhibits IL-1b and other pro-inflammatory IL-family members. IL-38 is a potential therapeutic cytokine which inhibits inflammation in viral infections including that caused by COVID-19, providing a new relevant strategy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Wang, C., Pan, R., Wan, X., Tan, Y., Xu, L., McIntyre, R. S., Choo, F. N., Tran, B., Ho, R., Sharma, V. K., et al. (2020) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2020.04.028 · Cited by 2,571
Zhang, W., Zhao, Y., Zhang, F., Wang, Q., Li, T., Liu, Z., Wang, J., Qin, Y., Zhang, X., Yan, X., et al. (2020) · Clinical Immunology · doi:10.1016/j.clim.2020.108393 · Cited by 1,266
SARS-CoV-2 infection: The role of cytokines in COVID-19 disease
Costela-Ruiz, V. J., Illescas-Montes, R., Puerta-Puerta, J. M., Ruiz, C., & Melguizo-Rodríguez, L. (2020) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2020.06.001 · Cited by 1,121
Immune response to SARS‐CoV‐2 and mechanisms of immunopathological changes in COVID‐19
Azkur, A. K., Akdis, M., Azkur, D., Sokolowska, M., van de Veen, W., Brüggen, M., O’Mahony, L., Gao, Y., Nadeau, K., & Akdis, C. A. (2020) · Allergy · doi:10.1111/all.14364 · Cited by 1,119
Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial
Chen, Z., Hu, J., Zhang, Z., Jiang, S., Han, S., Yan, D., Zhuang, R., Hu, B., & Zhang, Z. (2020) · medRxiv · doi:10.1101/2020.03.22.20040758 · Cited by 847
Iba, T., Levy, J. H., Levi, M., & Thachil, J. (2020) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.14975 · Cited by 585
COVID-19: The Inflammation Link and the Role of Nutrition in Potential Mitigation
Zabetakis, I., Lordan, R., Norton, C., & Tsoupras, A. (2020) · Nutrients · doi:10.3390/nu12051466 · Cited by 532
Colunga Biancatelli, R. M. L., Berrill, M., Catravas, J. D., & Marik, P. E. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01451 · Cited by 512
Inhibition of Bruton tyrosine kinase in patients with severe COVID-19
Roschewski, M., Lionakis, M. S., Sharman, J. P., Roswarski, J., Goy, A., Monticelli, M. A., Roshon, M., Wrzesinski, S. H., Desai, J. V., Zarakas, M. A., et al. (2020) · Science Immunology · doi:10.1126/sciimmunol.abd0110 · Cited by 357
A metabolic handbook for the COVID-19 pandemic
Ayres, J. S. (2020) · Nature Metabolism · doi:10.1038/s42255-020-0237-2 · Cited by 292
COVID-19 gone bad: A new character in the spectrum of the hyperferritinemic syndrome?
Colafrancesco, S., Alessandri, C., Conti, F., & Priori, R. (2020) · Autoimmunity Reviews · doi:10.1016/j.autrev.2020.102573 · Cited by 268
Nano-curcumin therapy, a promising method in modulating inflammatory cytokines in COVID-19 patients
Valizadeh, H., Abdolmohammadi-vahid, S., Danshina, S., Ziya Gencer, M., Ammari, A., Sadeghi, A., Roshangar, L., Aslani, S., Esmaeilzadeh, A., Ghaebi, M., et al. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.107088 · Cited by 267
Necrostatin-1 and necroptosis inhibition: Pathophysiology and therapeutic implications
Cao, L., & Mu, W. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2020.105297 · Cited by 266
COVID-19 in kidney transplant recipients
Nair, V., Jandovitz, N., Hirsch, J. S., Nair, G., Abate, M., Bhaskaran, M., Grodstein, E., Berlinrut, I., Hirschwerk, D., Cohen, S. L., et al. (2020) · American Journal of Transplantation · doi:10.1111/ajt.15967 · Cited by 258
Zhang, M., Wang, P., Luo, R., Wang, Y., Li, Z., Guo, Y., Yao, Y., Li, M., Tao, T., Chen, W., et al. (2021) · Advanced Science · doi:10.1002/advs.202002928 · Cited by 236
Carubbi, F., Salvati, L., Alunno, A., Maggi, F., Borghi, E., Mariani, R., Mai, F., Paoloni, M., Ferri, C., Desideri, G., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-83831-8 · Cited by 104
Investigating Ketone Bodies as Immunometabolic Countermeasures against Respiratory Viral Infections
Stubbs, B. J., Koutnik, A. P., Goldberg, E. L., Upadhyay, V., Turnbaugh, P. J., Verdin, E., & Newman, J. C. (2020) · Med · doi:10.1016/j.medj.2020.06.008 · Cited by 71
Mesenchymal stem cell immunomodulation: in pursuit of controlling COVID-19 related cytokine storm
Song, N., Wakimoto, H., Rossignoli, F., Bhere, D., Ciccocioppo, R., Chen, K.-S., Khalsa, J. K., Mastrolia, I., Samarelli, A. V., Dominici, M., et al. (2021) · Stem Cells · doi:10.1002/stem.3354 · Cited by 62
Hamidi, S. H., Kadamboor Veethil, S., & Hamidi, S. H. (2021) · Pharmacological Reports · doi:10.1007/s43440-021-00255-x · Cited by 50
Al Mahmeed, W., Al-Rasadi, K., Banerjee, Y., Ceriello, A., Cosentino, F., Galia, M., Goh, S.-Y., Kempler, P., Lessan, N., Papanas, N., et al. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.787761 · Cited by 48
Ahmed-Hassan, H., Sisson, B., Shukla, R. K., Wijewantha, Y., Funderburg, N. T., Li, Z., Hayes, D., Demberg, T., & Liyanage, N. P. M. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01979 · Cited by 47
Mitigation of influenza-mediated inflammation by immunomodulatory matrix-bound nanovesicles
Crum, R. J., Huckestien, B. R., Dwyer, G., Mathews, L., Nascari, D. G., Hussey, G. S., Turnquist, H. R., Alcorn, J. F., & Badylak, S. F. (2023) · Science Advances · doi:10.1126/sciadv.adf9016 · Cited by 25
Modifications of IL-6 by Hypochlorous Acids: Effects on Receptor Binding
Robins, L. I., Keim, E. K., Robins, D. B., Edgar, J. S., Meschke, J. S., Gafken, P. R., & Williams, J. F. (2021) · ACS Omega · doi:10.1021/acsomega.1c05297 · Cited by 12
Metadata
- Authors
- Conti, P.
- Venue
- Journal of Biological Regulators and Homeostatic Agents
- Published
- 2020-03
- Volume
- 34
- Issue
- 2
- Pages
- 1
- ISSN
- 0393-974X (ISSN-L)
- OpenAlex
- W3012405893
- Cited by
- 1,227
- References
- 0
- FWCI
- 33.95
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
